OMER, Israel, May 8, 2014 (GLOBE NEWSWIRE) -- Medigus Ltd. (TASE: MDGS), a medical device company developing minimally invasive endosurgical tools and procedures, announced today that Nissim Darvish, M.D, Ph.D., Chairman of the Board and Senior Managing Director at OrbiMed Israel Partners healthcare fund, will participate in a Medical Device Panel at the Oppenheimer 15th Annual Israeli Conference. The Panel will be dedicated to Israeli traded medical device companies facing clinical, marketing and financial challenges. The panel will take place on Sunday, May 11, 2014, at 10:15 a.m. Israeli local time. The conference will take place at the David InterContinental Hotel in Tel Aviv, Israel.
About Oppenheimer 15th Annual Israeli Conference
Oppenheimer Israel, Israel's leading broker in foreign investments, together with Nasdaq OMX are arranging and sponsoring Oppenheimer's annual conference since 2004. The conference will include opening remarks by Mr. Erel Margalit, a member of the Knesset, Labour Party, and founder of Jerusalem Venture Partners JVP, followed by Simultaneous companies' presentations, with more than 60 Israeli companies traded in the US slated to attend this year's conference. The broad-based list of guests includes Israeli Institutionals: insurance companies, pension funds, provident funds, mutual funds, banks, venture capitals, family offices and money managers. Based on the response to the previous years' events, Oppenheimer expects the conference to attract approximately 500 participants as well as considerable media coverage.
About Medigus
Medigus is leading the transition from invasive gastric surgery procedures to less invasive, patient-friendly techniques through the development of minimally invasive endoscopic devices and procedures. The company's revolutionary MUSE(TM) System enables endoscopists and surgeons to treat gastroesophageal reflux disease (GERD), a chronic disease with increasing global prevalence, by performing a fundoplication procedure through the mouth. Unlike current fundoplication procedures, the MUSE(TM) system does not require abdominal incisions, which may result in shorter post-procedure recovery. The MUSE(TM) System (previously known as SRS(TM) System for transoral fundoplication) has received FDA clearance and CE mark. Medigus is traded on the TASE (Tel Aviv Stock Exchange). To learn more about the company's minimally invasive technology platform, please visit http://www.medigus.com/.
###
MEDIA CONTACT:
Chantal Beaudry/Martyna Gawrych
Lazar Partners Ltd.
212-867-1762
cbeaudry@lazarpartners.com
mgawrych@lazarpartners.com
INVESTOR RELATIONS:
Miri Segal-Scharia
Hayden/ MS-IR LLC
917-607-8654
msegal@ms-ir.com
HUG#1783685